Each point was worked out with the data available that day. Scale 0-10: 5 is the index average and 10 is the cap (+3 standard deviations), not perfection. The vertical axis zooms to fit this company, so two charts are not comparable by eye.
Market and Valuation
Price & Market
Prev Close Price:$84.76
Open:$84.55
Day's Low:$82.81
Day's High:$85.18
Bid / Ask:-
Market Cap:30.94B
Enterprise Value:31.19B
52-Week Range
52-Week Low:$54.11
52-Week High:$92.59
Current position in 52-week range
52w Low-52w High
50-Day Avg:$85.67
200-Day Avg:$74.64
Volume
Volume Today:4,123,104
Avg Volume (3m):4,425,900
Avg Volume (10d):6,159,770
52-Week Change:+38.54%
vs S&P 500, 52 weeks:-
Beta:1.44
Valuation Multiples
P/E (trailing):32.67
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 29, 2026. The P/E is the price divided by that EPS.
P/E (forward):26.47
PEG Ratio:1.40
Price / Book:12.21
Price / Sales (TTM):6.06
EV / Revenue:6.11
EV / EBITDA:20.81
Dividends
Current yield:-
Annual Dividend Rate:-
Dividend Trailing:$0.00
Yield Trailing:0.00%
5-Year Avg Yield:-
Payout Ratio:0.00%
Last Ex-Dividend Date:-
Valuation Context
P/E vs sector (indicative)
Most Recent Quarter:-
Fiscal Year (Next):-
Loading historical OHLCV database...
Date
Open
High
Low
Close
Volume
Financial Statements TTM (Trailing 12 Months)
Income Statement
Total Revenue (TTM):5.10B
Gross Profit:3.24B
EBITDA:1.50B
Net Income (TTM):991.00M
Rev Growth (YoY):+11.20%
Earnings Growth (YoY):+2.60%
Quarterly earnings growth (YoY):-3.10%
Margins
Gross Margin:-
EBITDA Margin:-
Operating Margin:-
Net Margin:-
Per Share
EPS Trailing (TTM):$2.54
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 29, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$3.13
Revenue Per Share:$13.36
Cash Per Share:-
Book Value:$6.80
Last Dividend:-
Ex-Dividend Date:-
Last Split:-
Balance Sheet & Liquidity
Total cash:1.82B
Total Debt:1.39B
Net Debt (Debt - Cash):−425.00M (net cash)
Debt / Equity:54.94%
Current Ratio:1.74
Quick Ratio:1.34
Cash Flows
Operating Cash Flow:1.41B
Free Cash Flow (FCF):811.90M
FCF Yield (FCF / Market Cap):-
Enterprise Value:31.19B
EV / Revenue:6.11
EV / EBITDA:20.81
Profitability
ROE (Return on Equity):37.67%
ROA (Return on Assets):11.14%
P/E (trailing):32.67
P/E (forward):26.47
Price / Book:12.21
PEG Ratio:1.40
52-Week Change:+38.54%
S&P 500 change, 52 weeks:+11.37%
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
EPS Trailing (TTM):$2.54
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 29, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$3.13
P/E (forward):26.47
PEG Ratio:1.40
Growth and Margins
Earnings Growth YoY:-
Quarterly Earnings Growth YoY:-
Rev Growth YoY:-
Net Margin:-
Gross Margin:-
EBITDA Margin:-
Per Share
Revenue Per Share:$13.36
Cash Per Share:-
Book Value:$6.80
Cash Flows (TTM)
Free Cash Flow:811.90M
Operating Cash Flow:1.41B
EBITDA:1.50B
Total Revenue (TTM):5.10B
Net Income (TTM):991.00M
Fiscal Year (Last):-
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
Quarter
Period
Actual EPS
Estimated EPS
Difference
Surprise %
Currency
Ownership Structure
Ownership Distribution
% Insiders:-
% Institutional:-
% Inst. (of Float):-
No. of Institutions:-
Visual distribution
InsidersInstitutionalFree Float
Shares & Short Interest
Shares Outstanding:372,950,922
Float (free shares):371,597,110
Short interest (shares):15,690,510
Short % of float:-
Short Ratio (days to cover):3.91
Short interest, prior month:-
Short Interest Date:-
Governance Score (1=Best, 10=Worst)
Overall risk:-
Audit Risk:-
Board risk:-
Compensation Risk:-
Shareholder rights risk:-
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
Organization
Report Date
% Shares
No. Shares
Value (USD)
Change %
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
Fund
Report Date
% Shares
No. Shares
Value (USD)
Change %
Recent Insider Trades
Executive / Insider
Title
Date
Action
Shares
Options Chain
CALLS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
PUTS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
Sentiment Metrics
Put/Call Ratio (Volume):-
Put/Call Ratio (O.I.):-
Max Pain (estimated):-
Total O.I. Calls:-
Total O.I. Puts:-
Expected move
Average IV (Calls ATM):-
Average IV (Puts ATM):-
Days to Expiration:-
Expected move (±):-
DexCom, Inc. (DXCM) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.
No card. No spam.
DexCom, Inc. (DXCM): Quantitative Analysis
DexCom, Inc. (DXCM) — Healthcare — Medical Devices. DXCM is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.
So far in 2026, DXCM has returned +25.0% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.
DXCM ranks 98 of 461 on today's multifactor score, and 9 of the 55 Healthcare companies that score. Its strongest factor is momentum (Z 1.02, ranked 66 of 494); its weakest is value (Z -0.61, ranked 423 of 489). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.
Factor scores
The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.
DexCom has no announced date in the Nasdaq public calendar checked (Nov 3, 2026 to Dec 7, 2026). Of its last 12 earnings announcements: 12 after the close (SEC filings through Oct 29, 2026). DXCM earnings dates and times, quarter by quarter →
What is DexCom's P/E ratio?
DexCom's P/E (price over earnings per share for the last twelve months) is 32.7 at the Nov 3, 2026 close. That EPS is the 12-month diluted figure from the SEC, the four quarters ended Sep 30, 2026. The median of the 54 Healthcare companies with a P/E is 30.5, and the S&P 500's, 23.5: DexCom is above its sector median. Healthcare stocks, company by company →
Where does DexCom rank on Quant500?
In the Nov 3, 2026 multi-factor ranking, DexCom ranks 98 of 461, and 9 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking →How it is calculated →
Have DexCom insiders bought or sold shares?
The latest open-market purchase of DexCom shares filed with the SEC (Form 4) was on Nov 10, 2025, by an officer, for $1.0M. The latest sale was on Oct 27, 2026, by an officer, for $202k. In total, from August 2025 through Nov 3, 2026: 1 purchase and 32 sales by directors, officers and large shareholders. All DXCM insider trades →
What sector is DexCom in, and which index?
DexCom is classified in the Healthcare sector (industry: Medical Devices), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →
What is behind these numbers
The concepts on this page, explained from scratch in the Academy. Free, no account.
Quality and low volatilityWhere the quality score comes from, and why it is the factor with the most competing definitions, all of them called the same thing.
We save the portfolios you design, your own portfolio and your Academy progress, synced across devices.
Free, no card. Two automatic emails and no more: the one that confirms your address and the welcome one. After that, nothing you do not switch on yourself in your profile — such as the alert for insider buys, the same day they are reported to the SEC.